In the latest research, scientists from Canada tracked nearly 3,000 Americans who used either semaglutide, the active drug in ...

This peer-reviewed study, based on electronic health record data from more than 24,600 patients followed for over 4.7 years, found no e ...

Based on the feedback from the FDA, the Company’s regulatory data package would be sufficient for the submission of an sNDA for AXS-05 for the treatment of Alzheimer’s disease agitation. Axsome ...

Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing mobile clinical network ...

More information is available on www.ContraveHCP.com and www.Contrave.com.

Source: Getty Images At the 2024 Neuroscience Education Institute Scientific Congress, researchers Maxwell Price and Richard Price, MD presented on the promising effects of extended-release ...

Compared with placebo, extended-release naltrexone-bupropion combination therapy reduced total fat mass and improved the lean-to-fat mass ratio in individuals with obesity or overweight and ...

Currently, approved treatments for nicotine withdrawal include Bupropion and Varenicline, but there is a pressing need for new therapeutic options to improve smoking cessation success rates.

Currently, approved treatments for nicotine withdrawal include Bupropion and Varenicline, but there is a pressing need for new therapeutic options to improve smoking cessation success rates.

(Teva) resolving all patent litigation related to Axsome’s AUVELITY® (dextromethorphan HBr – bupropion HCl) product. The litigation resulted from submission by Teva of an Abbreviated New Drug ...